GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » Gross Margin %

Theralink Technologies (Theralink Technologies) Gross Margin % : 36.90% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Theralink Technologies's Gross Profit for the three months ended in Dec. 2023 was $0.03 Mil. Theralink Technologies's Revenue for the three months ended in Dec. 2023 was $0.08 Mil. Therefore, Theralink Technologies's Gross Margin % for the quarter that ended in Dec. 2023 was 36.90%.


The historical rank and industry rank for Theralink Technologies's Gross Margin % or its related term are showing as below:

THER' s Gross Margin % Range Over the Past 10 Years
Min: 60.39   Med: 73.98   Max: 79.24
Current: 73.39


During the past 13 years, the highest Gross Margin % of Theralink Technologies was 79.24%. The lowest was 60.39%. And the median was 73.98%.

THER's Gross Margin % is ranked better than
66.22% of 749 companies
in the Biotechnology industry
Industry Median: 60.63 vs THER: 73.39

Theralink Technologies had a gross margin of 36.90% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Theralink Technologies was 0.00% per year.


Theralink Technologies Gross Margin % Historical Data

The historical data trend for Theralink Technologies's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies Gross Margin % Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 71.27 76.68 60.39 79.24

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.00 84.71 75.25 77.65 36.90

Competitive Comparison of Theralink Technologies's Gross Margin %

For the Biotechnology subindustry, Theralink Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Gross Margin % falls into.



Theralink Technologies Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Theralink Technologies's Gross Margin for the fiscal year that ended in Sep. 2023 is calculated as

Gross Margin % (A: Sep. 2023 )=Gross Profit (A: Sep. 2023 ) / Revenue (A: Sep. 2023 )
=0.5 / 0.607
=(Revenue - Cost of Goods Sold) / Revenue
=(0.607 - 0.126) / 0.607
=79.24 %

Theralink Technologies's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0.084
=(Revenue - Cost of Goods Sold) / Revenue
=(0.084 - 0.053) / 0.084
=36.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Theralink Technologies  (OTCPK:THER) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Theralink Technologies had a gross margin of 36.90% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Theralink Technologies Gross Margin % Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralink Technologies (Theralink Technologies) Business Description

Traded in Other Exchanges
N/A
Address
15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.
Executives
Danica Holley director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz director 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors director 1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin director, officer: Chief Executive Officer HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc 10 percent owner 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett officer: Chief Executive Officer 230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb director PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman 10 percent owner, officer: Chief Operating Officer-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme director, 10 percent owner, officer: Global Operations GM-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman director C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: CFO & President 549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head director, officer: Chief Executive Officer 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817